(NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020. Financial Highlights: Revenue of $166.9 million for the fourth quarter of 2020, an increase of 14.9% compared to the fourth quarter of 2019. Excluding the impact of the voluntary recall (a non-GAAP measure) 1, revenue of $172.7 million for the fourth quarter of 2020, an increase of 18.9% compared to the same quarterly period a year ago or an increase of 17.7% in constant currency (a non-GAAP measure) 1. US revenue of $116.8 million for the fourth quarter of 2020 was 21.6% above the same period a year ago. Revenue of $560.4 million